Measuring Soluble CD44 in Colorectal Cancer Patients
Author Information
Author(s): Masson D, Denis M G, Denis M, Blanchard D, Loirat M J, Cassagnau E, Lustenberger P
Primary Institution: Laboratoire de Biochimie Médicale, Faculté de Médecine, Nantes, France
Hypothesis
Can soluble CD44 levels in plasma serve as a serum marker for colorectal cancer?
Conclusion
Patients with colorectal cancer have higher levels of soluble CD44 in their plasma compared to healthy individuals, but no significant difference was found between colorectal cancer and gastrointestinal disease patients.
Supporting Evidence
- The concentration of sCD44 was significantly higher in patients with colorectal cancer compared to healthy individuals.
- No significant differences in sCD44 levels were found between colorectal cancer patients and those with gastrointestinal diseases.
- No association was found between plasma sCD44 levels and cancer staging.
Takeaway
This study looked at a substance called soluble CD44 in the blood of people with colorectal cancer and found that they had more of it than healthy people.
Methodology
Blood plasma specimens were analyzed using ELISA assay and purification techniques.
Limitations
No specific sCD44 isoform was linked to cancer staging or other biological information.
Participant Demographics
89 patients with colorectal neoplasm, 22 with gastrointestinal disease, and 23 healthy donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website